Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.

Joao GorgulhoChristoph RoderburgFabian BeierCarsten BokemeyerTim Henrik BrümmendorfSven H LoosenTom Luedde

Published in: British journal of cancer (2024)

Pending prospective validation, sLAG3 and correlating circulating T-cell subsets can be used as a non-invasive predictive marker to predict outcome to ICI therapy to help identifying ideal ICI candidates in the future.

Keyphrases

patients undergoing
peripheral blood
copy number
genome wide
current status